Trial Profile
Randomized, Double-blind, Multi-center Phase III Clinical Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine and Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Amlodipine/rosuvastatin/telmisartan (Primary)
- Indications Essential hypertension; Hyperlipidaemia
- Focus Therapeutic Use
- Sponsors Ildong Pharmaceutical
- 20 Mar 2019 Primary endpoint (Percentage of change in LDL-Cholesterol) has been met as per results published in the Clinical Therapeutics
- 20 Mar 2019 Results published in the Clinical Therapeutics
- 10 Sep 2018 New trial record